Boehringer Ingelheim’s Survodutide Shows Promise in Late‑Stage Obesity Trials
Boehringer Ingelheim’s Survodutide Shows Strong Weight‑Loss Results in Late‑Stage Trial
Eli Lilly’s Next‑Gen Obesity Pill Shows Promise for Sleep Apnea and More
PCOS: A Metabolic Rethink – Why a New Study is Shaking Up How We Understand This Condition
Structure Therapeutics CEO Charts Course for Next-Gen Obesity Treatments
The Prize Fight for Progress: Pfizer Snags Metacrine in a High-Stakes Metabolic Drug Scramble
The Billion-Dollar Standoff: Pfizer Unleashes on Novo Nordisk in Metsera Bid Battle
The Great Weight Shift: Biotech's Quest for What's Next in Obesity Care
Novo Nordisk Secures Future in Liver Disease, Acquires Akero Therapeutics in Landmark Deal
The Silent Threat Within: How Common Fatty Liver Transforms into a Deadly Disease
The Silent Epidemic: How Obesity is Fueling a Surge in Early-Onset Type 2 Diabetes
Pfizer's Bold Gambit: Unleashing New Weapons in the Global Battle Against Obesity
The Silent Epidemic: How Malnutrition Fuels a Hidden Form of Diabetes